Drug Trial Radar · NCT01360866
Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)
Last checked: Nov 19, 2026Latest source record: Sep 17, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,944
Actual
Start
Oct 2011
Primary completion
Apr 18, 2017
Study completion May 18, 2017
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
- Sponsor type
- Industry
- First posted
- May 26, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess the long-term safety and tolerability of oral OPC-34712 (brexpiprazole), given in addition to an FDA approved antidepressant (ADT) for the treatment of adults with Major Depressive Disorder (MDD)
Conditions
- Depressive Disorder
- Depression
- Depressive Disorder, Major
- Mood Disorders
- Mental Disorders
Interventions
OPC-34712Drug
Tablet
EscitalopramDrug
Tablet
FluoxetineDrug
Capsule
Paroxetine CRDrug
Controlled-release tablets
SertralineDrug
Tablets
DuloxetineDrug
Delayed-release capsules
Venlafaxine XRDrug
Extended-release capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Events (AEs) - All ParticipantsTime frame: From screening to week 52/early termination
Locations
142 sites in 11 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Phoenix, Arizona
Research Site
Little Rock, Arkansas
Research Site
Beverly Hills, California
Research Site
Costa Mesa, California
Research Site
Glendale, California
Research Site
Irvine, California
Research Site
Oceanside, California
Research Site
Redlands, California
Research Site
San Diego, California
Research Site
San Francisco, California
Research Site
Santa Ana, California
Research Site
Sherman Oaks, California
Research Site
Temecula, California
Research Site
Upland, California
Research Site
Norwalk, Connecticut
Research Site
Coral Gables, Florida
Research Site
Coral Springs, Florida
Research Site
Fort Myers, Florida
Research Site
Gainesville, Florida
Research Site
Hialeah, Florida
Research Site
Jacksonville, Florida
Research Site
Jacksonville Beach, Florida
Research Site
Melbourne, Florida
Research Site
Miami, Florida
Research Site
Miami Springs, Florida
Research Site
Oakland Park, Florida
Research Site
Orlando, Florida
Research Site
The Villages, Florida
Research Site
Winter Park, Florida
Research Site
Alpharetta, Georgia
Research Site
Atlanta, Georgia
Research Site
Decatur, Georgia
Research Site
Smyrna, Georgia
Research Site
Oak Brook, Illinois
Research Site
Indianapolis, Indiana
Research Site
Lafayette, Indiana
Research Site
Prairie Village, Kansas
Research Site
Wichita, Kansas
Research Site
Lake Charles, Louisiana
Showing 40 of 142 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.